Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16355729 | 0.88 | ITGB3 (0.55) | ITGB3ITGA2BCTSLCTSKP2RX7 | |
| SCHEMBL9219338 | 0.88 | CTSK (0.62) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL19485480 | 0.88 | CTSK (0.62) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL25320494 | 0.87 | HDAC8 (0.58) | ITGB3ITGA2BCTSLCTSKP2RX7 | |
| SCHEMBL9995844 | 0.86 | CTSK (0.60) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL2058584 | 0.86 | CTSK (0.60) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL15018841 | 0.86 | CTSK (0.60) | ITGB3ITGA2BCTSLCTSKCTSB | |
| SCHEMBL22457264 | 0.85 | CTSL (0.61) | ITGB3ITGA2BCTSLCTSKP2RX7 | |
| Water SCHEMBL15019511 | 0.85 | CTSS (0.62) | ITGB3ITGA2BCTSLCTSKCTSB | |
| Water SCHEMBL15019510 | 0.85 | CTSS (0.62) | ITGB3ITGA2BCTSLCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | ITGB3 4757/4885ITGA2B 3890/4885CTSL 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.